4D Molecular Therapeutics, Inc. Common Stock (FDMT) — Analysis Summary
4D Molecular Therapeutics, Inc. Common Stock (FDMT) has a market cap of $590.72M with year-over-year revenue growth of +230194.6%. Net margin stands at -164.4%. The stock trades at a P/E ratio of -3.7.
Key Takeaways
- Revenue changed +230194.6% year-over-year
- Net margin of -164.4%
- P/E ratio of -3.7
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, FDMT posted revenue growth of +230194.6% and trades at a P/E of -3.7.
4D Molecular Therapeutics, Inc. Common Stock (FDMT)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -203.5% — severe operating losses
Net margin at -182.3% — losses exceed revenue (possible one-time charges)
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
196
Headquarters
EMERYVILLE, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.